Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Live Streamed

On Demand

414 Views

Z5. COVID-19 Complications, co-infections, and clinical outcomes

Poster Session: COVID-19: Complications, Coinfections and Clinical Outcomes

(P-1928) Virologic and Clinical Outcomes Among Participants Hospitalized in a Phase 3 Trial Comparing Molnupiravir with Placebo for Treating Mild-to-Moderate COVID-19

Saturday, October 19, 2024

12:15 PM – 1:30 PM US PT

Location: Halls JK

Presenting Author(s)

Matthew G. Johnson, MD (he/him/his)

Sr Principal Scientist, Clinical Research
Merck & Co., Inc.
Rahway, New Jersey, United States

David W. Hilbert, PhD

Associate Principal Scientist
Merck Research Laboratories
Rahway, New Jersey, United States
EJ

Erin Jensen, MS

Principal Scientist
Merck & Co., Inc.
Kenilworth, NJ, United States
DM

Dorothy McCoy, PharmD

Merck & Co., Inc.
Rahway, New Jersey, United States
Brian Maas, PharmD

Associate Principal Scientist
Merck & Co., Inc.
YZ

Ying Zhang, PhD

Merck & Co., Inc.
Rahway, New Jersey, United States
MB

Michelle L. Brown, BS

Associate Director, Clinical Scientist
Merck & Co., Inc.
Kenilworth, New Jersey, United States
DB

Dana L. Byrne, MD

Merck & Co., Inc.
Rahway, New Jersey, United States
CD

Carisa S. De Anda, PharmD

Executive Director, Clinical Research
Merck & Co., Inc.
Kenilworth, NJ, United States